World renowned topic experts will be discussing C. difficile infection (CDI) prevention, treatments, clinical trials, research, environmental safety products, Fecal Microbiota Transplantation (FMT), IBS, Microbiome, SIBO, Sepsis, Nutrition, and a special presentation given by a panel of C. diff. survivors and much more. Visit the 2017 Conference Page For Details and Registration.
U.S. Hot-Line: 1-844-FOR-CDIF (1-844-367-2343)
International: Country Code 1 + Area Code 919 + Number 201-1512
U.S. Main Number: 919-201-1512
Healthcare Providers, and Triage Nurses are available to speak with Monday through
Friday 9:00 a.m. ET – 5:00 p.m. ET with limited on-call weekends, to learn more about C. diff. Prevention, Diagnosis, Symptoms and Transmission Treatments, Environmental Safety and Support Worldwide.
Previous studies indicate that C. difficile has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone. The new study found that 1 out of every 5 patients with a healthcare-associated C. difficile infection experienced a recurrence of the infection and 1 out of every 9 patients aged 65 or older with a healthcare-associated
C. difficile infection died within 30 days of diagnosis.** (1)
The epidemiology of C. diff. infections in the UK:
The height of the epidemic of C. diff. infections in the UK was towards the end of the last decade. There are comprehensive UK data on CDI because of a mandatory reporting system that was introduced over 10 years ago; in England there were ~60 000 cases in 2007-08, with large, hospital based outbreaks, some of which led to multiple official reviews of healthcare practice. Major government-led public health campaigns followed, which included the use of targets for every NHS hospital, financial penalties if targets were missed, and (in 2012) standardized testing for CDI across the NHS. These interventions led to an 80% reduction in CDI rates and in CDI associated mortality; in England there
were ~14 000 cases in 2013-14. There was a small rise in CDI’s (~6% in 2014-15), which is unexplained. CDI remains a key performance management condition in the NHS, and so low rates are considered as a marker of high quality healthcare. (2)
There is validation enough for the C Diff Foundation to continue its’ dedication in lowering morbidity and mortality rates through continued education, advocating, and sharing the C Diff Foundation mission in raising C. diff. awareness with healthcare professionals, healthcare students, healthcare facilities, patients, families, and communities – working towards a shared goal ~ To witness a reduction of newly diagnosed C. diff. cases on a global level — by 2020.
The C Diff Foundation works closely within the healthcare industry, from villages to cities in thirty-eight countries with patients, and in many industries addressing the problems and discussing solutions focused on C. difficile, a common healthcare-associated infection (HAI). “International Raising C.diff. Awareness” takes place through Summits, Symposiums, Workshops, and Annual Conferences each year. The first annual “International Raising C Diff Awareness” Conference was held in November 2013 and brought together some of the best minds in epidemiology and healthcare with new ideas regarding the challenges the world is facing in C.diff. prevention, treatments, and environmental safety. By and through presenting specific, scientific data to meet C. diff. challenges, encouraging healthcare professionals, healthcare organizations, and pharmaceutical organizations to share the
information and providing scientific data being utilized to implement C. diff. solutions.
“Our Foundation is without borders as our outreach expands over horizons dedicated in our mission; Educating and advocating for C. difficile infection prevention, treatments, support, and environmental safety worldwide to end the suffering from this infection and help save lives.” states
Nancy C. Caralla, Foundress, Executive Director
“None of us can do this alone…..all of us can do this together!”
PLEASE TAKE 20 MINUTES TO ANSWER THIS
SURVEY — HELP US TO HELP OTHERS —
“Clostridium difficile is the most common
health care-associated pathogen. Its consequences on the quality of life of patients lack data. If you face or faced a Clostridium difficile infection, please take 20 minutes to answer this survey: https://cdiffsurvey.org.
The purpose of this study is to evaluate the consequences of Clostridium difficile infections (CDI), if existing, on the quality of life of patients during the acute infection. This study will also explore the post-CDI symptoms that patients might experience.
This study will help physicians, healthcare providers and policy makers understand the burden of CDI and to strengthen the need for therapies to combat and prevent CDI. ”
JOIN US and Share Our Mission To Save Lives Worldwide!
To speak with an Information Specialist regarding
C. diff. infection prevention, treatments, and environmental safety products
call the U.S. Nationwide Hot-Line 1-844-FOR- CDIF (1-844-367-2343) or e-mail questions to: email@example.com
*Please Read Disclaimer Thank you. *
* If you are, or you know someone who is, experiencing
symptoms of a C. difficile infection, please contact a Physician and seek medical
(2) Dr. Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health England in the UK, C Diff Foundation: Chairperson, Medical Advisory Board.
SIGN UP for C Diff Foundation 365 Monthly Newsletter